Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.5%

Centessa Pharmaceuticals plc (NASDAQ:CNTA)’s stock price fell 3.5% on Friday . The stock traded as low as $12.20 and last traded at $12.63. 13,543 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 308,243 shares. The stock had previously closed at $13.09.

Analyst Ratings Changes

A number of equities analysts have weighed in on CNTA shares. Morgan Stanley boosted their price target on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday.

Centessa Pharmaceuticals Price Performance

The business’s 50 day simple moving average is $9.80 and its 200-day simple moving average is $9.88. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -8.93 and a beta of 1.40. The company has a quick ratio of 10.37, a current ratio of 10.37 and a debt-to-equity ratio of 0.36.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, research analysts forecast that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Quarry LP bought a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $48,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals in the first quarter worth about $109,000. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $90,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 69.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after purchasing an additional 4,423 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.